Author: Michelle Dryden

Categories
Science Technology

Investigational combination of Aliqopa® (copanlisib) and rituximab significantly increases progression-free survival in patients with relapsed indolent non-Hodgkin’s Lymphoma

  • In the Phase III trial CHRONOS-3 of 458 patients with indolent non-Hodgkin’s Lymphoma (iNHL), the investigational combination of Aliqopa and rituximab was statistically significant in delaying disease progression or death (HR=0.52, 95% CI 0.39, 0.69) compared to rituximab and placebo, with a median progression-free survival (PFS) of 21.5 months (95% CI 17.8, 33.0) versus 13.8 months (95% CI 10.2, 17.5)1
  • The CHRONOS-3 trial included several prespecified iNHL subgroups including follicular lymphoma (FL; n=275), marginal zone lymphoma (MZL; n=95), small lymphocytic lymphoma (SLL; n=50), and lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM; n=38)1
  • Bayer is discussing the data from CHRONOS-3 with health authorities worldwide

Abstract: CT001

WHIPPANY, N.J. — (BUSINESS WIRE) — Results from the randomized, double-blind, placebo-controlled Phase III trial CHRONOS-3 show a significant improvement in progression-free survival (PFS) with the investigational combination of Aliqopa® (copanlisib) and rituximab given intravenously in patients with relapsed indolent non-Hodgkin’s Lymphoma (iNHL) compared to the combination of rituximab and placebo. After a median follow-up of 19.2 months, patients treated with this combination had a median PFS of 21.5 months (95% CI 17.9, 33.0) versus 13.8 months in patients treated with rituximab and placebo (95% CI 10.2, 17.5), (HR=0.52, p=0.000002). No new safety signals were identified for Aliqopa in the combination arm of the study.1 The data will be presented in a Clinical Trials Plenary Session on April 10 at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 and simultaneously published in The Lancet Oncology.

CHRONOS-3 is a Phase III randomized, double-blind, placebo-controlled trial with the objective to evaluate whether Aliqopa in combination with rituximab is superior to placebo plus rituximab in extending PFS in patients with relapsed iNHL following at least one prior rituximab-containing therapy. Patients who had a progression-free and treatment-free interval of at least 12 months after completion of the last rituximab-containing regimen or patients unwilling/unfit or for who chemotherapy was contraindicated by reason of age, co-morbidities and/or residual toxicity were included.2

In 2017, Aliqopa was approved for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies based on the results of a single-arm, multicenter, Phase II clinical trial (CHRONOS-1).3 Accelerated approval was granted for this indication based on overall response rate (ORR). Continued approval for this indication is contingent upon verification and description of clinical benefit in a confirmatory trial.

“In clinical practice, we have seen an overall improvement in the prognosis of iNHL patients, yet relapsed disease is still a prominent treatment challenge,” said Matthew J. Matasar, M.D., Medical Oncologist, Regional Care Network Medical Site Director, Memorial Sloan Kettering Cancer Center (MSK) Bergen. “The results reported with the combination of copanlisib and rituximab suggest a potential advancement for patients with these diverse types of cancers.”

“Bayer is committed to putting patients’ needs first and delivering innovative treatment options that address areas of high unmet need, and clinical research is the first step in that process,” said Scott Z. Fields, M.D., Senior Vice President and Head of Oncology Development at Bayer. “These data highlight the potential of Aliqopa and rituximab as a new strategy for treating these patients and we look forward to advancing regulatory discussions.”

Bayer is in discussions with health authorities worldwide regarding the data from CHRONOS-3.

Additional CHRONOS-3 Data Being Presented at AACR

In addition to the primary endpoint of PFS, data on the secondary endpoints of ORR and complete response rate (CRR) will also be presented. Best ORR for the combination of Aliqopa and rituximab was 80.8% (95% CI 76, 85) versus 47.7% (95% CI 40, 56) for rituximab and placebo (p<0.0001), with 33.9% and 14.6% of patients achieving CR, respectively. Of the relapsed iNHL patients included in the trial, 60% had FL, 20.7% marginal zone lymphoma (MZL), 10.9% small lymphocytic lymphoma (SLL) and 8.3% lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM). Analysis of the subtypes will be presented at AACR and published in The Lancet Oncology.1

All-grade treatment-emergent adverse events (TEAEs) observed with the Aliqopa and rituximab combination that occurred in more than 20% of the patients included hyperglycemia (69.4%), hypertension (49.2%), diarrhea (33.6%), neutropenia (20.8%), nausea (22.5%) and pyrexia (20.5%). Discontinuation due to all-grade TEAEs in CHRONOS-3 for Aliqopa and rituximab was 32% versus 8% for rituximab and placebo.1

Aliqopa is an intravenous phosphatidylinositol-3-kinase (PI3K) inhibitor with predominant activity against alpha and delta isoforms the PI3K-alpha and PI3K-delta isoforms expressed in malignant B cells.4 Aliqopa is approved in the U.S. under the accelerated approval pathway for the treatment of adult patients with relapsed FL who have received at least two prior systemic therapies. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Accelerated approval was granted for this indication based on an ORR of 59% (n=61/104; 95% CI 49, 68), including 14% (15/104) of CRs from the open-label, single-arm multicenter, Phase II clinical trial (CHRONOS-1), in a total of 142 subjects, which included 104 subjects with follicular B-cell non-Hodgkin’s Lymphoma who had relapsed disease following at least two prior treatments. In the updated two-year follow-up analysis conducted on data until 16 weeks after the last patients eligible for full analysis started treatment, Aliqopa ORR was 59% (n=61; 95% CI 49, 68), including 20% CR (n=21).5 Tumor response was assessed according to the International Working Group response criteria for malignant lymphoma. Efficacy based on ORR was assessed by an Independent Review Committee.

Disclosure: This study was sponsored by Bayer AG. Dr. Matasar has received honoraria from Bayer AG and subsidiaries of Bayer AG for advising and related activities. Bayer AG also provides research funding for Dr. Matasar through Memorial Sloan Kettering Cancer Center (MSK). In addition, Dr. Matasar has received honoraria from Roche/Genentech for advising and related activities, and the company also provides research funding for him through MSK.

About Aliqopa® (copanlisib) Injection3

Aliqopa (copanlisib) is indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. Accelerated approval was granted for this indication based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Aliqopa is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3K-α and PI3K-δ isoforms expressed in malignant B cells. Aliqopa has been shown to induce tumor cell death by apoptosis and inhibition of proliferation of primary malignant B cell lines. Aliqopa inhibits several key cell-signaling pathways, including B-cell receptor signaling, CXCR12 mediated chemotaxis of malignant B cells, and NFκB signaling in lymphoma cell lines.

IMPORTANT SAFETY INFORMATION FOR ALIQOPA® (copanlisib)

Infections: Serious, including fatal, infections occurred in 19% of 317 patients treated with ALIQOPA monotherapy. The most common serious infection was pneumonia. Monitor patients for signs and symptoms of infection and withhold ALIQOPA for Grade 3 and higher infection.

Serious pneumocystis jiroveci pneumonia (PJP) infection occurred in 0.6% of 317 patients treated with ALIQOPA monotherapy. Before initiating treatment with ALIQOPA, consider PJP prophylaxis for populations at risk. Withhold ALIQOPA in patients with suspected PJP infection of any grade. If confirmed, treat infection until resolution, then resume ALIQOPA at previous dose with concomitant PJP prophylaxis.

Hyperglycemia: Grade 3 or 4 hyperglycemia (blood glucose 250 mg/dL or greater) occurred in 41% of 317 patients treated with ALIQOPA monotherapy. Serious hyperglycemic events occurred in 2.8% of patients. Treatment with ALIQOPA may result in infusion-related hyperglycemia. Blood glucose levels typically peaked 5 to 8 hours post-infusion and subsequently declined to baseline levels for a majority of patients; blood glucose levels remained elevated in 17.7% of patients one day after ALIQOPA infusion. Of 155 patients with baseline HbA1c <5.7%, 16 (10%) patients had HbA1c >6.5% at the end of treatment.

Of the twenty patients with diabetes mellitus treated in CHRONOS-1, seven developed Grade 4 hyperglycemia and two discontinued treatment. Patients with diabetes mellitus should only be treated with ALIQOPA following adequate glucose control and should be monitored closely.

Achieve optimal blood glucose control before starting each ALIQOPA infusion. Withhold, reduce dose, or discontinue ALIQOPA depending on the severity and persistence of hyperglycemia.

Hypertension: Grade 3 hypertension (systolic 160 mmHg or greater or diastolic 100 mmHg or greater) occurred in 26% of 317 patients treated with ALIQOPA monotherapy. Serious hypertensive events occurred in 0.9% of 317 patients. Treatment with ALIQOPA may result in infusion-related hypertension. The mean change of systolic and diastolic BP from baseline to 2 hours post-infusion on Cycle 1 Day 1 was 16.8 mmHg and 7.8 mmHg, respectively. The mean BP started decreasing approximately 2 hours post-infusion; BP remained elevated for 6 to 8 hours after the start of the ALIQOPA infusion. Optimal BP control should be achieved before starting each ALIQOPA infusion. Monitor BP pre- and post-infusion. Withhold, reduce dose, or discontinue ALIQOPA depending on the severity and persistence of hypertension.

Non-infectious Pneumonitis: Non-infectious pneumonitis occurred in 5% of 317 patients treated with ALIQOPA monotherapy. Withhold ALIQOPA and conduct a diagnostic examination of a patient who is experiencing pulmonary symptoms such as cough, dyspnea, hypoxia, or interstitial infiltrates on radiologic exam. Patients with pneumonitis thought to be caused by ALIQOPA have been managed by withholding ALIQOPA and administration of systemic corticosteroids. Withhold, reduce dose, or discontinue ALIQOPA depending on the severity and persistence of non-infectious pneumonitis.

Neutropenia: Grade 3 or 4 neutropenia occurred in 24% of 317 patients treated with ALIQOPA monotherapy. Serious neutropenic events occurred in 1.3%. Monitor blood counts at least weekly during treatment with ALIQOPA. Withhold, reduce dose, or discontinue ALIQOPA depending on the severity and persistence of neutropenia.

Severe Cutaneous Reaction: Grade 3 and 4 cutaneous reactions occurred in 2.8% and 0.6% of 317 patients treated with ALIQOPA monotherapy respectively. Serious cutaneous reaction events were reported in 0.9%. The reported events included dermatitis exfoliative, exfoliative rash, pruritus, and rash (including maculo-papular rash). Withhold, reduce dose, or discontinue ALIQOPA depending on the severity and persistence of severe cutaneous reactions.

Embryo-Fetal Toxicity: Based on findings in animals and its mechanism of action, ALIQOPA can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of copanlisib to pregnant rats during organogenesis caused embryo-fetal death and fetal abnormalities in rats at maternal doses as low as 0.75 mg/kg/day (4.5 mg/m2/day body surface area) corresponding to approximately 12% the recommended dose for patients. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment and for at least one month after the last dose.

Adverse Drug Reactions: Serious adverse reactions were reported in 44 (26%) patients. The most frequent serious adverse reactions that occurred were pneumonia (8%), pneumonitis (5%) and hyperglycemia (5%). Adverse reactions resulted in dose reduction in 36 (21%) and discontinuation in 27 (16%) patients. The most frequently observed adverse drug reactions (≥20%) in ALIQOPA-treated patients were: hyperglycemia (54%), leukopenia (36%), diarrhea (36%), decreased general strength and energy (36%), hypertension (35%), neutropenia (32%), nausea (26%), thrombocytopenia (22%), and lower respiratory tract infections (21%).

Drug Interactions: Avoid concomitant use with strong CYP3A inducers. Reduce the ALIQOPA dose to 45 mg when concomitantly administered with strong CYP3A inhibitors.

Lactation: Advise women not to breastfeed. Advise a lactating woman not to breastfeed during treatment with ALIQOPA and for at least 1 month after the last dose.

For important risk and use information about Aliqopa, please see the full Prescribing Information.

About CHRONOS-3

CHRONOS-3 is a Phase III randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Aliqopa in combination with rituximab versus placebo in combination with rituximab in patients with relapsed indolent NHL who have received at least one or more lines of prior rituximab-containing therapy. Histological subtypes included in the trial were follicular lymphoma (FL), small lymphocytic lymphoma (SLL), lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM), and marginal zone lymphoma (MZL). Patients who had a progression-free and treatment-free interval of at least 12 months after completion of the last rituximab-containing regimen or patients unwilling/unfit or for who chemotherapy was contraindicated by reason of age, co-morbidities and/or residual toxicity were included (NCT02367040). The study enrolled 458 participants.2

About non-Hodgkin’s Lymphoma

Non-Hodgkin’s Lymphoma (NHL) comprises a highly heterogeneous group of chronic diseases with poor prognosis. NHL is the most common hematologic malignancy and the eleventh most common cancer worldwide, with nearly 510,000 new cases diagnosed in 2018. It accounted for nearly 249,000 deaths worldwide in 2018.6,7

Indolent NHL consists of multiple subtypes, including follicular lymphoma (FL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), and lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM). While the disease is typically slowly growing, it can become more aggressive over time. Despite treatment advances, there remains a need for improved treatment options for the relapsed or refractory stage of the disease. After response to initial therapy, response rates and duration of response decline with subsequent lines of therapy, underscoring the need for patients whose disease has already progressed.

About Oncology at Bayer

Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer now expands to six marketed products and several other assets in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.com.

© 2021 Bayer

BAYER, the Bayer Cross and Aliqopa are registered trademarks of Bayer.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

______________________________________________________________________________

References

  1. Matasar, M., Capra, M., Özcan, M., et.al. CHRONOS-3: randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL) CT001. In: Proceedings of the 112th Annual Meeting of the American Association for Cancer Research; 2021 April 10-15. Philadelphia (PA): AACR; 2021. Abstract CT001
  2. ClinicalTrials.gov. Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin’s Lymphoma (iNHL) (CHRONOS-3). Available online: https://clinicaltrials.gov/ct2/show/NCT02367040. Last Accessed: March 2021.
  3. Aliqopa (copanlisib) for injection [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; November 2020.
  4. Scott, W.J., Hentemann, M.F., Rowley, R.B., et al. ChemMedChem 2016, 11, 1517-1530. Discovery and SAR of novel 2,3-dihydroimidazo[1,2-c]quinazoline PI3K inhibitors: Identification of copanlisib (BAY 806946).
  5. Dreyling, M., Santoro, A., Mollica, L., et al. J. Hematol. 2020, 95, 362-371. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
  6. World Cancer Research Fund. Worldwide cancer data: Global cancer statistics for the most common cancers. Available online: https://www.wcrf.org/dietandcancer/cancer-trends/worldwide-cancer-data. Last Accessed: March 2021
  7. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018), Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68: 394-424. https://doi.org/10.3322/caac.21492

PP-ALI-US-0689-1 04/21

Contacts

Media Contact:
Rose Talarico, Tel. +1 862.404.5302

E-Mail: rose.talarico@bayer.com

Categories
Business Technology

Vision Solar, a cutting edge renewables company projected to exceed $150M for 2021, hires seasoned CIO, Greg Young, to drive its innovation and digital transformation

BLACKWOOD, N.J. — (BUSINESS WIRE) —#renewables — On March 17th, Vision Solar, which is one of the leaders in Residential Solar Panel Installations, found their “purple unicorn,” and announced Greg Young as their new Chief Information Officer.

Young is a candidate with a profile that possesses the skills and experiences that are rare. Vision Solar with its forward-thinking digital transformation and innovative trajectory, is happy to have Young join their diverse leadership team.

Greg Young has over 20 years of professional experience within the Information Technology Industry. Prior to joining Vision Solar, Greg Young served as Chief Information Officer and Global Vice President for Hardinge Inc. It was here that Young created a proven successful record in integrating scalable technology solutions. His experiences have given him the ability to continuously deliver value by driving organizations to break through operational and performance success.

 

“I’m very excited to join Vision Solar during this time of exponential growth. I look forward to helping the company grow through innovation,” Young stated.

Young’s goal in his new position is to lead Vision Solar’s digital transformation journey by delivering cutting-edge and scalable solutions that drive business results, and provide a competitive edge that differentiates us within Renewables space, in all of our current and future locations, nationwide.


About Vision Solar

Vision Solar is one of the fastest growing solar energy companies in the United States. Their full-service renewable energy company installs solar services for residential homes in Pennsylvania, Arizona, New Jersey, Massachusetts and Florida. Over the past three years, Vision Solar has grossed over $100 million in revenue, with significant increase in projected growth to produce 1000+ high-quality Green Jobs by 2022. To learn more, visit: https://visionsolar.llc

Contacts

John Czelusniak,

jczelusniak@visionsolar.llc

Categories
Business

Organon announces pricing of senior notes offering

KENILWORTH, N.J. — (BUSINESS WIRE) — Organon Finance 1 LLC, a subsidiary of Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Organon Finance 1 LLC has priced its previously announced offering of €1,250,000,000 aggregate principal amount of 2.875% senior secured notes due 2028 (the “euro secured notes”), $2,100,000,000 aggregate principal amount of 4.125% senior secured notes due 2028 (the “U.S. dollar secured notes”) and $2,000,000,000 aggregate principal amount of 5.125% senior unsecured notes due 2031 (the “unsecured notes” and together with the euro secured notes and U.S. dollar secured notes, the “notes”), in connection with the previously announced spinoff of Organon & Co. (“Organon”) from Merck. As part of the spinoff, the notes will be assumed by Organon, and a Dutch private limited company and wholly owned subsidiary of Organon which will act as co-issuer of the notes.

Organon intends to use the net proceeds from the notes offering, together with available cash on its balance sheet and borrowings under senior secured credit facilities which Organon anticipates entering into, to repay one or more intercompany loans or notes owed by Organon to a Merck affiliate and to pay fees and expenses related to the spinoff. The proceeds of the notes offering will be held in escrow until satisfaction of the conditions precedent to the spinoff and certain other escrow release conditions (the “Effective Date”).

Each series of notes will be issued at an issue price of 100%. From and after the Effective Date, the euro secured notes and the U.S. dollar secured notes will be guaranteed on a senior secured basis, and the unsecured notes will be guaranteed on a senior unsecured basis, jointly and severally, by all of Organon’s existing or future subsidiaries that guarantee its proposed senior secured credit facilities. Prior to the Effective Date, each series of notes will be senior secured obligations solely of the Organon Finance 1 LLC, and will not be guaranteed by Organon or any of its subsidiaries.

The notes offering is expected to close on April 22, 2021, subject to customary closing conditions.

The notes have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), any state securities laws or the securities laws of any other jurisdiction, and may not be offered or sold in the United States absent registration or an applicable exemption from registration. Accordingly, the notes are being offered and sold only to persons reasonably believed to be qualified institutional buyers in accordance with Rule 144A under the Securities Act and to non-U.S. persons outside the United States in reliance on Regulation S under the Securities Act.

This announcement is an advertisement and is not a prospectus for the purposes of Regulation (EU) 2017/1129 (as amended, the “Prospectus Regulation”) or Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (the “UK Prospectus Regulation”).

In member states of the European Economic Area, this announcement is directed only at persons who are “qualified investors” within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement is directed only at persons who are “qualified investors” within the meaning of the UK Prospectus Regulation.

Manufacturer target market (MiFID II product governance / UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs key information document has been prepared as not available to retail in the EEA. No UK PRIIPs key information document has been prepared as not available to retail in the UK.

In the United Kingdom, this announcement is directed only at persons (i) that have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”); (ii) falling within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations etc.”) of the Order; or (iii) at whom this announcement may otherwise be directed without contravention of Section 21 of the Financial Services and Markets Act 2000, as amended (all such persons together being referred to as “relevant persons”). This announcement must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Organon

Organon will be a global healthcare company formed through a spinoff from Merck to focus on improving the health of women throughout their lives. It will have a portfolio of more than 60 trusted medicines that address an entire spectrum of conditions women face. Led by the growing reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health. In addition, Organon will pursue opportunities to partner with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast-growing international markets.

Organon is expected to have a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, N.J.

About Merck

For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements include statements with respect to the company’s plans to spinoff certain of its businesses into an independent company, the timing and structure of such spinoff, the characteristics of the business to be separated, the expected benefits of the spinoff to the company and the expected effect on the company’s dividends. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to whether the proposed spinoff will be completed on the proposed timetable or at all. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, uncertainties as to the timing of the proposed spinoff; uncertainties as to the status of any required regulatory approvals; the possibility that various conditions to the consummation of the spinoff may not be satisfied; the effects of disruption from the transactions contemplated in connection with the spinoff; general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; the impact of the global outbreak of novel coronavirus disease (COVID-19); global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Contacts

Media Contacts:

Patrick Ryan

(973) 275-7075

Jessica Fine

(908) 608-4859

Investor Contacts:

Peter Dannenbaum

(908) 740-1037

Raychel Kruper

(908) 740-2107

Categories
Business

American Water publishes first annual Inclusion & Diversity Report

CAMDEN, N.J.–(BUSINESS WIRE)–American Water (NYSE: AWK), the largest publicly traded U.S. water and wastewater utility company, announced today that it has released its first annual Inclusion & Diversity Report.

“At American Water, we regularly reflect on our values and our culture. This report highlights the efforts we have undertaken and the strides we have made advancing the company’s commitment to inclusion and diversity,” said Walter Lynch, President and CEO, American Water. “We are committed to building a diverse and inclusive culture that reflects the communities we serve.”

The report shares through a transparent lens the inclusion and diversity strategies, practices, policies, and programs from across the business. It includes more than 100 data points related to American Water’s culture of inclusion and caring. The report also exemplifies how the company is constantly striving, thanks to the contributions of every employee, to build an inclusive and mutually respectful workplace.

“We’re stronger because we have different ideas, viewpoints, experiences and backgrounds,” said Valoria Armstrong, Chief Inclusion Officer and Vice President of External Affairs, American Water. “Most importantly, we embrace and encourage one another to respect and value those differences. At American Water, we believe that inclusion and diversity are vital elements to our success.”

American Water has received various awards and recognitions demonstrating our commitment to inclusion & diversity, examples include:

  • Awarded 2020 National Corporation of the Year by Eastern Minority Supplier Development Council
  • Top scoring (100%) company on the Disability Equality Index
  • Top 100 Best for Vets Employers by Military Times
  • Inclusion in the 2021 Bloomberg Gender-Equality Index
  • Named a 2020 DiversityInc Noteworthy Company

The full report can be found in the Inclusion & Diversity section of the company’s website.

About American Water

With a history dating back to 1886, American Water is the largest and most geographically diverse U.S. publicly traded water and wastewater utility company. The company employs more than 7,000 dedicated professionals who provide regulated and market-based drinking water, wastewater and other related services to 15 million people in 46 states. American Water provides safe, clean, affordable and reliable water services to our customers to help make sure we keep their lives flowing. For more information, visit amwater.com and follow American Water on Twitter, Facebook and LinkedIn.

Contacts

Media Contact:
Joseph Szafran

External Affairs Manager

856-955-4304

joseph.szafran@amwater.com

Categories
Entertainment News

Miranda Lambert’s MuttNation & Tractor Supply Co. donate $250,000 to animal shelters

Mutts Across America Gives Surprise Grants to 50 Animal Shelters, One in Each State

NASHVILLE, Tenn. — (BUSINESS WIRE) — Miranda Lambert’s MuttNation Foundation and Tractor Supply Company have teamed up to provide a quarter-million dollars in grants through MuttNation’s Mutts Across America program. A ‘surprise’ $5,000 donation will be made to one shelter or foster-based rescue in each state across the country. Organizations are carefully researched and vetted before honoring one outstanding nonprofit in each state.


Bev Lambert, Miranda’s mom and co-founder of MuttNation, who conceived Mutts Across America seven years ago said, “There are so many fantastic organizations doing such great work that selecting the final shelters is always the hardest part.”

Miranda added, “This was our first signature program and it’s our cornerstone. It lets us reward the hard-working rescues and celebrate shelter pets everywhere. It hits all the high notes.” The GRAMMY, CMA and ACM award winning, multi-platinum recording artist continued, “We’re so honored to have Tractor Supply Company as our partner. We’re accomplishing so much together and, thanks to their incredibly generous support, this year’s gifts to the shelters will be the most impactful ever. Given the fundraising difficulties rescues have faced over the past year, we know it will make a huge difference to thousands of animals.”

“At Tractor Supply, we love our four-legged friends and appreciate this opportunity to demonstrate our ongoing support for animal shelters across the country.” said Nicole Logan, Vice President, Divisional Merchandise Manager at Tractor Supply Company. “Miranda’s passion and tremendous dedication dovetails with our mission at Tractor Supply to care for all pets and animals. We are excited to expand our partnership with Miranda and the MuttNation organization to make this the most impactful Mutts Across America yet.”

In addition to this donation, Tractor Supply is the exclusive retailer of MuttNation products. A percentage of all sales goes to the MuttNation Foundation to further support the cause.

Since the initiative’s inception, MuttNation’s Mutts Across America has supported more than 350 shelters with over $1.25 million in grants. Here are this year’s recipients:

SHELTER NAME STATE SHELTER NAME STATE
Heart of Alabama Save Rescue Adopt Alabama RezQ Dogs Montana
Straw For Dogs Alaska 12 Hills Dog Rescue Nebraska
Arkansans Assisting Homeless Animals (AAHA) Arkansas Churchill Animal Protection Society Nevada
Friends for Life Animal Rescue Arizona Conway Area Humane Society New Hampshire
Sally’s Rescue California Castle of Dreams Animal Rescue New Jersey
Great Pyrenees Rescue and Sanctuary Colorado Sunflower Sanctuary Animal Rescue New Mexico
Double Dog Rescue Connecticut Badass Brooklyn Animal Rescue New York
Grass Roots Rescue Delaware Humane Society of Union County North Carolina
The Farm Dog Rescue Florida Furry Friends of Rockin’ Rescue North Dakota
Angels Among Us Pet Rescue Georgia Canine Collective Ohio Dog Rescue Ohio
Kaaawa K9 Rescue Hawaii Second Chance Animal Sanctuary Oklahoma
Idaho Humane Society Idaho Three Rivers Humane Society Oregon
Hope Rescues Illinois Home At Last Dog Rescue Pennsylvania
Heaven After Hell Rescues Indiana Heart of Rhode Island Animal Rescue League Rhode Island
AHeinz57 Pet Rescue & Transport, Inc. Iowa Concerned Citizens for Animals South Carolina
LL Dog Rescue Kansas Hopeless To Homes Animal Rescue South Dakota
Tyson’s Chance Kentucky Friends of Williamson County Tennessee
Rescue Rehome Repeat Louisiana Friends of Marshall Animals Texas
Rescue Charlie’s Friends Maine Rescue Rovers Dog Adoptions Utah
Baltimore Animal Rescue & Care Shelter Maryland Passion 4 Paws Vermont
Sweet Paws Rescue Massachusetts Homeless Animals Rescue Team Virginia
AuCaDo: Australian Cattle Dog Rescue Michigan Motely Zoo Animal Rescue Washington
Pawsitivity Minnesota Animal Welfare Society of Jefferson County West Virginia
Dixie Adoptables At Lucedale Animal Shelter Mississippi Coco’s Heart Dog Rescue Wisconsin
Needy Paws Rescue Missouri Kindness Ranch Animal Sanctuary Wyoming

About MuttNation Foundation

Founded by Miranda and her mom, Bev Lambert, in 2009, MuttNation is a donation-supported 501(c)(3) nonprofit organization with a mission to promote the adoption of shelter pets, advance spay & neuter and educate the public about the benefits of these actions. MuttNation also works with transport partners to assist and relocate animals under threat of euthanasia and during times of natural disaster. With a goal of finding a forever home for every shelter animal, MuttNation supports animal rescues across the country, hosts adoption events throughout the year, provides positive reinforcement for the shelter adoption experience, works to raise awareness for its causes and develops and implements initiatives to further its mission-driven goals. www.muttnation.com

About Miranda Lambert

Vanner Records/RCA recording artist Miranda Lambert released her highly anticipated new studio album, Grammy-nominated Wildcard, on Nov. 1, 2019, which includes her #1 Grammy-nominated country radio single “Bluebird,” her latest single “Settling Down” and the Grammy-nominated single “It All Comes Out in The Wash.”

The most decorated artist in the history of the Academy of Country Music, Lambert is the recipient of more than 70 prestigious awards and special honors: 35 ACM Awards (including 9 ACM Female Vocalist of the Year Awards), 14 CMA Awards (Country Music Association), 2 GRAMMY Awards, the Harmony Award (Nashville Symphony), Artist in Residence (Country Music Hall of Fame), the ACM Gene Weed Milestone Award, ACM Song of the Decade Award, and was named 2019 RIAA’s Artist of the Year.

The celebrated singer/songwriter has released seven studio albums that all debuted at No. 1 on the Billboard Top Country Album Charts, including the critically acclaimed Wildcard (2019), The Weight of These Wings (2016), Platinum (2014), Four The Record (2011), Revolution (2009), Crazy Ex-Girlfriend (2007) and Kerosene (2005). In addition, she released three albums with her trio, the Pistol Annies.

Her clothing and cowboy boot collection, Idyllwind, is a private-label brand sold at all Boot Barn stores nationwide. www.idyllwind.com

About Tractor Supply

Tractor Supply Company (NASDAQ: TSCO), the largest rural lifestyle retailer in the United States, has been passionate about serving its unique niche, targeting the needs of recreational farmers, ranchers and all those who enjoy living the rural lifestyle, for more than 80 years. Tractor Supply offers an extensive mix of products necessary to care for home, land, pets and animals with a focus on product localization, exclusive brands and legendary customer service for the Out Here lifestyle. With more than 42,000 Team Members, the Company’s physical store assets, combined with its digital capabilities, offer customers the convenience of purchasing products they need anytime, anywhere and any way they choose at the everyday low prices they deserve. At December 26, 2020, the Company operated 1,923 Tractor Supply stores in 49 states and an e-commerce website at www.TractorSupply.com.

Tractor Supply Company also owns and operates Petsense, a small-box pet specialty supply retailer focused on meeting the needs of pet owners, primarily in small and mid-size communities, and offering a variety of pet products and services. At December 26, 2020, the Company operated 182 Petsense stores in 25 states. For more information on Petsense, visit www.Petsense.com.

To stay up to date on all things for Life Out Here, follow Tractor Supply on Facebook, Instagram and Twitter.

Contacts

Abby Brown

abby.brown@finnpartners.com
615-610-0258

Categories
Technology

BAE Systems starts electronic warfare system production for U.S. Air Force F-15s

NASHUA, N.H.–(BUSINESS WIRE)–BAE Systems has received a $58 million contract from Boeing to start Low Rate Initial Production (LRIP) of the F-15 Eagle Passive Active Warning and Survivability System (EPAWSS) for the U.S. Air Force. The electronic warfare (EW) and countermeasures system provides advanced electromagnetic capabilities that protect pilots and help them maintain air superiority during their toughest missions.


“The start of EPAWSS production marks a critical milestone and is a testament to the dedication and commitment of our industry team,” said Jerry Wohletz, vice president and general manager of Electronic Combat Solutions at BAE Systems. “Our technology is cutting-edge, our factories are world-class, and our people are innovative and mission-focused.”

The all-digital EPAWSS enables pilots to monitor, jam, and deceive threats in contested airspace. The system combines multispectral sensors and countermeasures, industry-leading signal processing, microelectronics, and intelligent algorithms to deliver fully integrated radar warning, situational awareness, geolocation, and self-protection capabilities.

The successful completion of a series of rigorous flight tests, ground tests, and intensive technology demonstrations led to the U.S. Air Force decision to proceed with LRIP. During the program’s Engineering and Manufacturing Development phase, BAE Systems is delivering incremental updates to the EPAWSS flight software with new geolocation and threat identification capabilities. As a result, system performance continues to improve in ground/flight test and in dense signal environments in hardware-in-the-loop (HiTL) tests at the U.S. Air Force’s Integrated Demonstrations and Applications Laboratory.

“I’m proud of the overall team for their incredible effort on this program,” said F-15 EPAWSS program manager Lt Col Dan Carroll. “The LRIP milestone is the culmination of years of hard work by a lot of great people within the government and our Boeing and BAE Systems industry partners. EPAWSS will significantly improve the survivability and utility of the F-15, and will be a great complement to what is already a very capable and lethal aircraft.”

BAE Systems has also demonstrated EPAWSS’ hardware maturity and manufacturing readiness. In anticipation of EPAWSS LRIP and other critical EW production needs, the company has invested more than $100 million in world-class EW laboratories and factories, and has grown its workforce of innovative, mission-focused experts.

Work on the EPAWSS program takes place at BAE Systems facilities in Nashua, New Hampshire; Austin, Texas; and Totowa, New Jersey.

Contacts

Mark Daly, BAE Systems

Mobile: 603-233-7636

mark.g.daly@baesystems.com

www.baesystems.com/US
@BAESystemsInc

Categories
Technology

IMM, Hawthorn River Lending Partner to accelerate digital transformation for community banks

–Digital loan origination solution enables end-to-end electronic processing helping banks close more loans, faster while providing an enhanced customer experience–

RAHWAY, N.J. — (BUSINESS WIRE) — IMM, the only eSignature provider that specializes in digital transaction solutions exclusively for financial institutions, and Hawthorn River, the developer of loan origination software for community banks, today announced the companies have partnered to provide an automated, end-to-end digital loan origination solution, helping community banks close more loans, faster, while enabling a more engaging, modern customer experience.

IMM eSign’s technology will now be integrated into Hawthorn River’s end-to-end, digital loan origination platform, further streamlining and automating the lending process. The integrated solution automatically processes document and facilitates a comprehensive, electronic environment while also providing customers a more dynamic, engaging experience whether in-branch or remote, enabling customers to complete lending transactions (from application to funding) at a time and place that is most convenient to them.

“The synergies between IMM and Hawthorn River were immediately evident, and we are pleased to partner with another technology provider that is focused exclusively on helping community financial institutions accelerate their digital transformation,” said Jon Rigsby, Co-Founder and CEO of Hawthorn River. “We consider IMM an extension of our team and together, our companies continue to collaborate on new and improved solutions that address and solve complex challenges facing community bankers. Our goal is to automate and streamline processes start-to-finish and the integrated solution we developed with IMM not only helps bankers be more productive and get more accomplished, it also provides the digital experience today’s consumer demands.”

Rigsby continued, “IMM also shares our passion for customer service and ensuring we are providing a solution that is tailored to meet the very unique needs of a community financial institution. That is something that is very important to our organization, and unfortunately, isn’t always the top priority for a lot of technology providers. We were immediately impressed with IMM’s commitment to service and recognized that culturally we were both in alignment on this key principle. I am proud of the work we’ve accomplished alongside IMM, and look forward to a long-standing partnership that will continue to benefit community banks for years to come.”

Hawthorn River’s ability to streamline lending by automating operational activities, proactively monitor compliance, and standardize end-to-end loan processes is further enhanced by IMM’s premier eSignature solution, IMM eSign. The integrated solution enables community banks to reduce costs and manual errors, improve security and compliance, while also providing a seamless, streamlined interface for bank employees to create and submit transactions for eSignature. Automating this process and eliminating the chance for human error is critical to creating a comprehensive end-to-end transaction lifecycle.

“Together, IMM and Hawthorn River will continue to exceed borrowers’ desires and expectations,” said Michael Ball, Senior Vice President of markets and strategy at IMM. “Both organizations are driven by their desire to create the best, most valuable products and services for financial institutions. Our partnership with Hawthorn will continue our mission to lead digital transformation for the banking community.”

Powering millions of end-to-end digital transactions each month, IMM eSign seamlessly interfaces with existing business systems to optimize back-office operations and provide a more dynamic and engaging customer experience. The transaction experience is frictionless and easy to use for financial institution employees while maintaining the safety and security for customers to sign documents remotely. IMM is the only eSignature provider that specializes in eSignature and Digital Transaction solutions exclusively for financial institutions.

About IMM

For 24 years, IMM has been the premier provider of eSignature and Digital Transaction solutions designed exclusively for financial institutions. Today, more than 1,300 banks and credit unions use IMM’s eSignature and Digital Transaction Management solutions across the Institution to elevate consumer experiences while streamlining back-office processes in a comprehensive, end-to-end digital processing environment.

For more information, visit www.immonline.com or call 1.800.836.4750. Follow us on LinkedIn, Facebook and Twitter.

About Hawthorn River

Hawthorn River is community banking software designed by community bankers. Our mission is to position community banks to remain competitive and independent in a rapidly consolidating industry. From streamlining the end-to-end lending process to automating specific steps along the way, Hawthorn River helps community banks increase productivity, reduce regulatory risk and elevate the borrower experience. For information, visit https://www.hawthornriver.com.

Contacts

For IMM:

Anna Stanley
anna@williammills.com
251.517.7857


For Hawthorn River:
Jon Rigsby
jrigsby@hawthornriver.com
314.220.5009

Categories
Business Entertainment News

“The Warrior Within Me” book released

Highlights: Self-Help *Christian beliefs* Author’s Journey & Struggles

POUGHKEEPSIE, N.Y.–(BUSINESS WIRE)–Issa Nesheiwat’s long journey capturing the guidance of Christianity to help overcome adversities, has been released by Palmetto Publishing. “The Warrior Within Me” is now available.

Nesheiwat, a Poughkeepsie, NY resident, promised God years ago to write the book, after his struggles, including an ordeal facing his family’s successful battle with leukemia.

Nesheiwat, 37, was born in Jordan, emigrated to New Jersey, and then moved to Yonkers, NY, where he attended school, and later, just three months before his high school graduation, moved to Poughkeepsie. His family now includes his wife and four children. Despite many successful business ventures, it is this book that was a work dream he has made reality.

“My life has been full of personal and family struggles, and with my knowledge of the Bible, my faith in God and my know how to get things done, I overcame my struggles, and felt it was important to share with others who seek either self help or help with similar situations,” Nesheiwat stated.

Central to Nesheiwat’s struggles was the years long battle his family faced with AML Leukemia. “I can tell you that with my knowledge of the Bible, my faith in God and my own desire to help my family and myself, I was able to persevere and share this story so people can help themselves through God and their inner beliefs,” added Nesheiwat.

Nesheiwat’s book is guided by six key principles: Spiritual warfare; understanding how trust engages faith; the truth about fear; why God chooses to communicate to us in our dreams; the importance of knowing biblical truth; and how frequency levels affect your life. Nesheiwat speaks of “The Real Secret,” which is missed in most self help books of this nature. The six principles, along with the current state of the individual’s mind and body, all play into how someone handles when they are tested in life.

Pastor Cano Rolon of Newburgh, NY stated that he was “humbled and blessed to have the honor to read this amazing book…I guarantee you that this book will edify your spirit.”

The book is available on Amazon and also on the book’s own website, www.thewarriorwithinmebook.com. Ebook and audible are also available on this website.

Contacts

Issa Nesheiwat, Author

issanesh@gmail.com
845-541-4567

Al Maiorino, Public Strategy Group, Inc

al@publicstrategygroup.com
617-859-3006

Categories
Business

Six Flags announces reopening of California and Mexico theme parks

Six Flags Mexico Opening March 18

Six Flags Magic Mountain and Six Flags Discovery Kingdom Opening April 1

ARLINGTON, Texas–(BUSINESS WIRE)–#Californiathemeparks—Six Flags Entertainment Corporation, the world’s largest regional theme park company and the largest operator of waterparks in North America, is reopening Six Flags Mexico today, March 18, 2021. Both of its California properties—Six Flags Magic Mountain and Six Flags Discovery Kingdom—will open to Members and Season Pass holders on April 1 and 2, and to the general public on April 3, 2021. The parks will operate at reduced attendance levels, in accordance with state reopening guidelines for theme parks, utilizing a reservation system. The parks will also implement extensive safety measures, including several new advanced technology systems used to protect guests and employees. The safety plan, developed in consultation with infectious disease experts and utilized throughout the Six Flags network of parks, sets standards for executing at the highest levels of hygiene and social distancing protocols. The parks will adjust these procedures as needed to ensure continued compliance with state recommendations.


“Californians are ready to visit their favorite Six Flags theme park and have some fun,” said Senior Vice President of Park Operations, Bonnie Weber. “Last year, we set the standard for safely operating our parks and entertained nearly seven million guests in adherence to government and CDC health guidelines. We will follow those same stringent guidelines as we reopen our rides and attractions in our California parks,” continued Weber.

Six Flags Magic Mountain’s Park President Don McCoy added, “Six Flags Magic Mountain is the undisputed Thrill Capital of the World, and we are excited to get our park open so that we can get our world-class collection of coasters running again. Our team is eager to return to work and entertain our guests in a safe environment, providing the much-needed fun and escape we have all missed this past year. I am also looking forward to seeing guests come out and experience West Coast Racers, our newest racing coaster that was open for only a brief time in 2020.”

Six Flags Discovery Kingdom’s Park President Janine Durette went on to say, “After safely and successfully operating The Marine World Experience for the past several months, we are thrilled to be able to offer our full selection of rides and attractions for the first time in over a year. Six Flags creates wonderful memories through the incredible experiences we provide guests of all ages. We are excited to welcome more guests to the park and to bring back more of our dedicated team members.”

Park reopening dates are subject to change based on local, state, and federal guidelines related to COVID-19. Detailed reopening plans include:

Park Reservations System to Control Capacity

Six Flags has established attendance caps that are in accordance with current state guidelines to allow for proper social distancing. All Members, Season Pass holders and all guests with a single-day or group ticket will need to make a reservation at www.sixflags.com/reserve. Guests who buy single day tickets will be able to reserve during the purchase process.

Protocols for the safe operation of rides

  • Easy-to-identify distance markers have been added in all ride queue lines;
  • Handrails, ride units, and restraints will be regularly sanitized throughout the day;
  • Riders on all roller coasters, rides, and attractions will be physically distanced in accordance with local and state guidelines; and
  • Masks must remain on while experiencing a ride or attraction.

Health Screenings for Guests and Team Members

  • Contactless IR thermal imaging will be used to screen temperatures of guests and employees prior to entry;
  • Advanced security screening technology will allow for touchless bag checks;
  • Individuals will be required to acknowledge and abide by the company’s health policies, which prohibits park entry if guests have recently been exposed to or are experiencing symptoms of COVID-19;
  • Following CDC guidelines, all guests over the age of two and all team members will be required to wear face masks covering the nose and mouth throughout their visit/work day; and
  • Disposable masks will be available at Guest Relations, and reusable masks will be available for purchase at in-park retail locations.

Strictly Enforced Social Distancing

  • Easy-to-identify distance markers have been added in all park entry, restroom, retail locations, and ride and dining queue lines;
  • Dining areas have been adjusted to allow ample space between seated parties;
  • Viewing areas are marked for guests to observe animal exhibits as well as game play, and arcade games have been reconfigured or deactivated to comply with social distancing requirements; and
  • Guests viewing outdoor entertainment will be separated by a minimum of six feet.

Extensive Sanitization and Disinfecting Protocols

  • Trained and dedicated cleaning teams have been put in place;
  • Increased sanitization and disinfecting of high touch points including all public seating, tabletops, counters, handrails, doors, and trash cans will occur frequently;
  • Restroom staff will be available to disinfect each stall and sink area on a frequent basis;
  • Multiple alcohol-based hand-sanitizer stations will be located throughout the park; and
  • All work areas will be regularly sanitized and disinfected.

Sanitized Food Preparation and Service

  • Modified menus and implementation of mobile food ordering will help facilitate touchless transactions;
  • Self-service buffets and salad bars will be reconfigured to eliminate guest contact with food;
  • Condiments, self-serve cutlery, and napkins will be provided to guests with their meals as required; and
  • Attendants will serve beverages, and guests will receive drink bottle refills in a paper cup each time they refill.

Commercial-Grade Cleaning Equipment and Supplies

  • All employees will be issued Team Member Action Packs which will include: two reusable face masks, safety glasses, and disposable gloves;
  • Low pressure backpack sprayers will be utilized for disinfecting large areas;
  • Abundant supplies of sanitizers and disinfectants will be available;
  • Microfiber cloths will be used to sanitize surfaces; and
  • Queue line supplies, fencing, and tents will be in place to promote safe social distancing.

Multi-Layered Guest and Team Member Communication

  • Frontline team members will go through extensive COVID-19 training;
  • Safety messaging and reminders will be communicated on Six Flags’ website, newsletters, and in-park announcements;
  • Distance markers and physical distance indicators will be in place; and
  • Informational safety signage will be posted throughout the park.

Virtual Hiring Fairs

As one of the largest seasonal employers in the country, Six Flags is currently hiring thousands of team members for the 2021 season. The safety of park guests, employees, and animals is always the company’s top priority, and applicants may now apply for jobs in a virtual and contact-free environment.

Open Parks

With today’s announcement, 21 of the company’s 26 parks are open or have approval to open for the 2021 season, and Six Flags continues to work with government officials to gain authorization for its remaining properties. The following parks have already opened, or will be opening soon, with a full complement of rides and attractions. Those parks include:

About Six Flags Entertainment Corporation

Six Flags Entertainment Corporation is the world’s largest regional theme park company and the largest operator of waterparks in North America, with 26 parks across the United States, Mexico, and Canada. For 59 years, Six Flags has entertained millions of families with world-class coasters, themed rides, thrilling waterparks and unique attractions. For more information, visit www.sixflags.com.

About Six Flags Magic Mountain

Six Flags Magic Mountain, known as the Thrill Capital of the World, is home to more than 100 rides, shows, and attractions, including world-class roller coasters like West Coast Racers, Twisted Colossus, Full Throttle, and X2.

About Six Flags Discovery Kingdom

Six Flags Discovery Kingdom, the Thrill Capital of Northern California, is home to more than 60 rides, shows, and attractions, including 10 world-class roller coasters like Medusa and Batman: The Ride. Six Flags Discovery Kingdom is the premier destination for thrilling, family fun.

About Six Flags Mexico

Six Flags Mexico is the premier theme park in Latin America. The park offers more than 40 rides and attractions for the entire family. A major tourist destination, Six Flags Mexico is celebrating its 20th anniversary season in 2021. For more information, visit www.sixflags.com.mx/mexico.

Follow us on Twitter @SixFlags @sfmagicmountain @sixflagsdk @SixFlagsMexico

Like us on Facebook at facebook.com/sixflags
Follow us on Instagram @sixflagsmagicmountain @sixflagsdiscoverykingdom @sixflagsmexico

Contacts

Sandra Daniels

972.595.5178

sdaniels@sftp.com

Categories
Business

Stocks climb more than 2% as investors get back to buying

 

In this photo provided by the New York Stock Exchange, traders work on the floor, Monday, March 1, 2021. Stocks are rising across the board on Wall Street as traders welcomed a move lower in long-term interest rates in the bond market. Investors were also watching Washington as a big economic stimulus bill moved to the Senate. (Courtney Crow/New York Stock Exchange via AP)

 

Stocks are rising across the board on Wall Street as traders welcomed a move lower in long-term interest rates in the bond market. Investors were also watching Washington as a big economic stimulus bill moved to the Senate.

 

The S&P 500 added 2.3% as of 12:25 p.m. Eastern. More than 95% of the stocks in the index were higher, led by energy and technology companies. The Dow Jones Industrial Average was up 642 points, or 2.1%, to 31,574 and the Nasdaq Composite rose 2.5%.

 

Much of the focus on Wall Street is on the bond market.

 

The yield on the 10-year Treasury note fell to 1.43% after going as high as 1.5% last week, the highest level in more than a year. Higher interest rates can slow the economy and discourage borrowing.

Bond yields, which influence interest ratest on mortgages and many other kinds of loans, have been steadily climbing much of the year, as investors have bet that vaccination efforts and more government stimulus will lead to strong economic growth this year. However, along with strong economic growth comes concerns of inflation.

 

A handful high-level officials with the Federal Reserve will make speeches this week, which will give investors additional information on how concerned the nation’s central bank is about the economy and inflation. Lael Brainard, an advocate for looser monetary policies, will give a monetary policy speech on Tuesday and Fed Chair Jerome Powell will give a speech on Thursday.

 

The House of Representatives approved Biden’s $1.9 trillion pandemic relief bill on Friday and it now goes to the Senate for approval. The bill infuses cash across the struggling economy to individuals, businesses, schools, states and cities battered by COVID-19.

 

The stimulus bill would include yet another round of one-time payments to most Americans, including an expansion of other refundable tax credits like the child tax credit, and additional aid to state and local governments to combat the pandemic.

 

Johnson & Johnson rose 1.5% after the Food and Drug Administration gave approval for the company’s own coronavirus vaccine, one that does not require extensive refrigeration like the ones made by Moderna and Pfizer.

 

Energy companies made some of the biggest gains. Exxon Mobil rose 5% and Occidental Petroleum rose 4.9%. Industrial companies, including airlines beaten down by the virus pandemic, also helped boost the broader market. United Airlines rose 3.4%.

 

Investors will get several big economic reports this week, including February’s jobs report on Friday. On Monday a report on manufacturing came in better than expectations, and new orders also came in better than expected.

 

— Associated Press